Adverse Events Following SARS-CoV-2 mRNA Vaccination: Among Patients with Inflammatory Bowel Disease

Am J Gastroenterol. 2021 May 25. doi: 10.14309/ajg.0000000000001342. Online ahead of print.


Gregory J Botwin 1, Dalin Li, Jane Figueiredo, Susan Cheng, Jonathan Braun, Dermot P B McGovern, Gil Y Melmed


Author information

  • 1Inflammatory Bowel and Immunobiology Research Institute, Karsh Division of Digestive and Liver Diseases Cedars-Sinai Cancer Departmet of Cardiology, Smidt Heart Institute, Cedars-Sinai, Los Angeles, CA 90048 Department of Medicine, Cedars-Sinai, Los Angeles, CA 90048 Department of Biomedical Sciences, Cedars-Sinai, Los Angeles, CA 90048.


Patients with immune-mediated inflammatory diseases (IMID) such as inflammatory bowel disease (IBD) on immunosuppressive and biologic therapies were largely excluded from SARS-CoV-2 mRNA vaccine trials. We thus evaluated post-mRNA vaccination adverse events (AE) in 246 vaccinated adults with IBD participating in a longitudinal vaccine registry. In general, AE frequency was similar to that reported in the general population. AE were more common among younger patients, and those with prior COVID-19. We additionally found that AE were less common in individuals receiving biologic therapy. Those with IBD and other IMID on these commonly prescribed therapies can be reassured that the AE risk is likely not increased, and may be reduced, while on biologics.

© Copyright 2013-2024 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.